Publications by authors named "Patrick J Roberts"

19Publications

Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows.

Mol Cancer Ther 2020 08 16;19(8):1575-1588. Epub 2020 Jun 16.

Center for Personalized Medicine, Roswell Park Cancer Institute, Buffalo, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-18-1161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473501PMC
August 2020

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.

Mol Cancer Ther 2016 05 29;15(5):783-93. Epub 2016 Jan 29.

G1 Therapeutics, Research Triangle Park, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0775DOI Listing
May 2016

Predicting drug responsiveness in human cancers using genetically engineered mice.

Clin Cancer Res 2013 Sep 18;19(17):4889-99. Epub 2013 Jun 18.

Lineberger Comprehensive Cancer Center, Department of Genetics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0522DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778918PMC
September 2013

Clinical use of crizotinib for the treatment of non-small cell lung cancer.

Biologics 2013 26;7:91-101. Epub 2013 Apr 26.

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S29026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643289PMC
May 2013

KRAS mutation: should we test for it, and does it matter?

J Clin Oncol 2013 Mar 11;31(8):1112-21. Epub 2013 Feb 11.

Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC 27599-7295, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.43.0454DOI Listing
March 2013

Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors.

Oncologist 2012 19;17(10):1303-16. Epub 2012 Sep 19.

University of North Carolina Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, 1013 Genetic Medicine Building, CB 7361, Chapel Hill, North Carolina 27599-7361, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2012-0274DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481896PMC
June 2013

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

J Natl Cancer Inst 2012 Mar 1;104(6):476-87. Epub 2012 Feb 1.

Department of Genetics, The University of North Carolina School of Medicine, Chapel Hill, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djs002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3309128PMC
March 2012

Posttranslational lipid modification of Rho family small GTPases.

Methods Mol Biol 2012 ;827:87-95

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-1-61779-442-1_6
Publisher Site
http://dx.doi.org/10.1007/978-1-61779-442-1_6DOI Listing
April 2012

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

J Clin Oncol 2010 Nov 4;28(31):4769-77. Epub 2010 Oct 4.

Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7295, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2009.27.4365
Publisher Site
http://dx.doi.org/10.1200/JCO.2009.27.4365DOI Listing
November 2010

Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification.

J Biol Chem 2008 Sep 9;283(37):25150-63. Epub 2008 Jul 9.

Lineberger Comprehensive Cancer Center, Division of Pharmacotherapy and Experimental Therapeutics, Department of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M800882200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2533093PMC
September 2008

The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans.

Drug Metab Dispos 2008 Aug 19;36(8):1465-9. Epub 2008 May 19.

Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.107.020065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770345PMC
August 2008